Dmitry Balyasny’s Aratana Therapeutics, Inc. PETX Stock Holding History

Dmitry Balyasny’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-33,210	Closed	-$141K	–	2235
2018 Q2	$141K	Buy	33,210 +2,802	+9%	+$14.1K	﹤0.01%	1684
2018 Q1	$134K	Buy	+30,408	New	+$136K	﹤0.01%	1807

Other funds holding PETX

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GPGA

Grandeur Peak Global Advisors Salt Lake City, Utah $432M AUM 42.58% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Dmitry Balyasny's PETX Position: Q3 2018 in Review

Dmitry Balyasny sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2018, closing a stake of 33,210 shares — an estimated $141K sold.

Dmitry Balyasny first reported a position in PETX in Q1 2018 and held it in 2 quarters. The position peaked at $141K in Q2 2018. 100 funds tracked by Wall St. Rank hold PETX as of Q3 2018.

Dmitry Balyasny reported no remaining Aratana Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
Dmitry Balyasny sold 33,210 Aratana Therapeutics, Inc. shares in Q3 2018, an estimated $141K.
Dmitry Balyasny first reported a position in Aratana Therapeutics, Inc. in Q1 2018 and held it in 2 quarters.
Dmitry Balyasny's Aratana Therapeutics, Inc. position peaked at $141K in Q2 2018.
100 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2018.

Based on Balyasny Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.